Using DNA Methylation to Improve Treatment for Salivary Gland Cancer
Harnessing Tumor and Circulating-Free DNA Methylation for Prognosis and Treatment Stratification in Adenoid Cystic Carcinoma
This study is looking at how changes in DNA can help doctors understand different types of adenoid cystic carcinoma, a kind of salivary gland cancer, by checking tumor samples and blood from patients to find clues that could improve treatment and track how the disease is doing.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10941953 on NIH RePORTER |
What this research studies
This research investigates how changes in DNA methylation can help identify different types of adenoid cystic carcinoma (ACC), a type of salivary gland cancer. By analyzing tumor samples and blood from patients, the study aims to find biomarkers that can predict disease behavior and guide treatment decisions. The researchers will examine the DNA methylation patterns in tumors and correlate them with patient outcomes to develop a non-invasive method for monitoring disease progression and treatment response.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with adenoid cystic carcinoma, particularly those with varying disease aggressiveness.
Not a fit: Patients with other types of cancers or those without a diagnosis of adenoid cystic carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment strategies for patients with adenoid cystic carcinoma, improving their prognosis and quality of life.
How similar studies have performed: Previous research has shown promise in using DNA methylation as a biomarker in other cancers, suggesting potential success for this novel approach in adenoid cystic carcinoma.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Ferrarotto, Renata — University of Tx Md Anderson Can Ctr
- Study coordinator: Ferrarotto, Renata
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.